Sinos wearable and app woman
Source: Sinos
Food and Drug Administration approved the first glucose monitoring system on Wednesday, especially for weight loss Startup SinosEstablish a new option for Americans to manage their weight.
Current treatment option to lose weight – Popular drugs like GLP-1s And surgical intervention – usually limited to obesity or a certain BMI patients. Obesity drugs like Novo nordiskK Vegovi and Ellie lilyIt can also be difficult to access due to its high cost, limited American insurance coverage and constrained supply.
But now, any patient can buy a sinos membership to reach their system. It uses an AI platform and an off-the-shelf constant glucose monitor, or CGM Dexcom To offer personal, real -time data and lifestyle recommendations for weight management.
“Now there is a solution that everyone can use to help in the journey of weight loss, and you should not have a certain number of pounds to use it. It is available to the average American, which it requires,” Sharam Foldgar-Masser, Sinos co-founder and CEO said in an interview on Tuesday. “Average person may have five pounds to lose, or others may have 100 pounds to lose. We are here to help them at any point in that journey.”
The cost of obesity epidemic is American health care system More than $ 170 billion in a yearAccording to the center of disease control and prevention data. About 74% of American suffers from overweight or obesity, Government data They say. Syneos hopes that it “can make a real big tooth in that curve for the betterment of many of us,” said Foldagar-Masser.
Customers who can sign up to sinos choose Three months or six months plan, which currently costs $ 139 and $ 129 respectively. The company will ship all the CGMs that they need for the number of months in the plan they choose.
The insurers currently do not cover the system for weight management, but the plans are a fraction of the GLP-1s of about $ 1,000 in the US sinos, working with health insurance companies and employers, to get coverage for the system, the company said in a statement to the CNBC. Syneos said that it hopes “it would grow quickly as the interest continued to expand to deal with weight.”
The sinos system can be used in combination with GLP -1S or bariatric surgery, said Fauldagar -Marser. He said that patients can use the system even after descending from GLP-1 to maintain their weight loss.
CGMs are small sensors worn on the upper hand that track glucose levels, mainly for people with diabetes. That data is sent wirelessly to the app of the sinos, which allows patients to log to their food intake and exercise levels, among other information that uses to make AI platforms recommendations.
In addition to helping people lose pounds, the system aims to help users understand how their bodies react to specific foods and exercise patterns and make correct behavior changes to manage and maintain their weight in the long term.
Sinos did not share how many patients are currently using their glucose monitoring system, but Foldagar-Masser said thousands of people have already tried it over time. He said that the sinos has scored its CGM inventory and software capacity to “handle a very large scale” after approval.
